Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382115 | 1.00 | TGFBR1 (0.40) | TGFBR1ACVR1CTSLCTSBCTSS | |
| SCHEMBL2382093 | 1.00 | TGFBR1 (0.40) | TGFBR1ACVR1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL2347286 | 0.99 | TGFBR1 (0.39) | TGFBR1ACVR1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL2348111 | 0.99 | TGFBR1 (0.39) | TGFBR1ACVR1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL2347290 | 0.99 | TGFBR1 (0.39) | TGFBR1ACVR1CTSLCTSBCTSS | |
| SCHEMBL2344152 | 0.96 | TGFBR1 (0.43) | TGFBR1ACVR1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL2348364 | 0.95 | TGFBR1 (0.43) | TGFBR1ACVR1CTSLCTSBCTSS | |
| SCHEMBL2383281 | 0.95 | TGFBR1 (0.44) | TGFBR1ACVR1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL2350451 | 0.94 | TGFBR1 (0.43) | TGFBR1ACVR1CTSLCTSBCTSS | |
| SCHEMBL2347737 | 0.90 | TGFBR1 (0.35) | TGFBR1ACVR1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011103091-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, NOD2, GPBAR1 | TGFBR1 570/4885ACVR1 1178/4885CTSL 1665/4885 |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | AGER, PSEN2, PSEN1 | TGFBR1 826/4885ACVR1 2247/4885CTSL 2004/4885 |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, PSEN2, PSEN1 | TGFBR1 826/4885ACVR1 2247/4885CTSL 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.